4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in 4D Molecular Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 96
- +8 vs. Q3 2022
- Shares held
- 28.0M
- +1.83M (+7.0%) vs. Q3 2022
- Total value
- $621.9M
- +$411.4M (+195.5%) vs. Q3 2022
- New holders
- 28
- 26 more added
- Sold out
- 20
- 32 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FDMT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 157 | $771.2M |
| Q1 2026 | 153 | $471.4M |
| Q4 2025 | 153 | $400.5M |
| Q3 2025 | 134 | $343.2M |
| Q2 2025 | 121 | $149.9M |
| Q1 2025 | 126 | $139.8M |
| Q4 2024 | 146 | $260.6M |
| Q3 2024 | 140 | $629.2M |
| Q2 2024 | 143 | $1.20B |
| Q1 2024 | 147 | $1.79B |
| Q4 2023 | 111 | $859.8M |
| Q3 2023 | 110 | $533.6M |
| Q2 2023 | 100 | $745.3M |
| Q1 2023 | 94 | $522.3M |
| Q4 2022 | 96 | $621.9M |
| Q3 2022 | 88 | $210.4M |
| Q2 2022 | 90 | $181.7M |
| Q1 2022 | 80 | $395.3M |
| Q4 2021 | 77 | $541.8M |
| Q3 2021 | 63 | $515.1M |
| Q2 2021 | 56 | $400.0M |
| Q1 2021 | 64 | $664.8M |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding 4D Molecular Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −37,044−100.0% | Sold out |
| UBS Asset Management Americas Inc | 0 | $0 | 0.00% | −26,894−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −23,997−100.0% | Sold out |
| Cornercap Investment Counsel Inc | 0 | $0 | 0.00% | −21,543−100.0% | Sold out |
| Alps Advisors Inc | 0 | $0 | 0.00% | −17,663−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −17,023−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −14,813−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −11,018−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −11,100−100.0% | Sold out |
| Resolute Partners Group | 0 | $0 | 0.00% | −9,600−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −7,180−100.0% | Sold out |
| Aquilo Capital Management, LLC | 0 | $0 | 0.00% | −3,573−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −2,300−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −2,114−100.0% | Sold out |
| Atlas Capital Advisors LLC | 0 | $0 | 0.00% | −675−100.0% | Sold out |
| Point72 Hong Kong Ltd | 0 | $0 | 0.00% | −50−100.0% | Sold out |